genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that further to the announcement of 29 November 2021, its rapid point of care Genedrive®COV19-ID Kit has received CE-IVD
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that further to the announcement of 29 November 2021, its rapid point of care Genedrive®COV19-ID Kit has received CE-IVD
Point-of-care Genedrive®COV19-ID submitted for CE-IVD certification Sets new benchmark in speed, accuracy and ease of use
York, U.K. 18 November 2021: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces its preliminary results for the year
AstraZeneca has decided to abandon the pledge of not-for profit made during the pandemic and aims to make a modest profit from COVID-19 vaccinations.
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces its audited Final Results for the year ended 30 June 2021.
London, UK – 29 September 2021: genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces that it has conditionally raised total gross proceeds of approximately £1.1 million through the
To help indicate the strength of antibody response and possible immunity
New Genedrive® system readied for Antibiotic Induced Hearing Loss launch
Contract manufacturing for CE marked self-test to monitor antibody status
Exclusive Lateral Flow Manufacturing Agreement with BioSure UK Limited
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, provides an update on the development of its Genedrive® COV19-ID Kit, a rapid Point of Care (PoC) molecular test for SARS-CoV-2
In addition to a potentially successful inhaled respiratory drug, SpectrumX Holdings Ltd has a commercial product that should generate significant sales in the near future. The respiratory drug is said